Molecular Diagnostics for Infectious Disease

SEE the Table of Contents.

GET the Free Sample of this Report.

Many organizations subscribe to some or all of our reports.  You may already have free access to this report. FIND out Here.

"Molecular Diagnostics for Infectious Disease By Syndrome, Plex, Place and by Country.  With Analysis and Executive Guides. 2026 - 2030"

“Technology is creating new markets segments and new diagnostic products.  Growth potential abounds in a market that is reinventing itself…”

 PAGES:  687

The Molecular Diagnostics – Infectious Disease sector of the clinical diagnostics industry is poised for new growth.  Find out what the numbers are in this informative report. And find out about the exciting technology developments  which threaten to change diagnosis and treatment while limiting the threat of anti microbial drug resistance.

Molecular diagnostics for infectious diseases refers to diagnostic technologies that detect nucleic acids associated with pathogens such as viruses, bacteria, fungi, and parasites. These tests identify genetic material from infectious organisms, allowing highly sensitive and specific detection of disease-causing agents. Molecular diagnostic methods have become essential tools in modern healthcare because they enable faster and more accurate diagnosis than many traditional microbiology techniques such as culture or antigen detection.

The global market for molecular diagnostics for infectious diseases is estimated to be USD 10.33 billion annually in 2025. The market is expected to grow to 12.9 Billion in 2030 for a CAGR of 4.5%.  The market experienced rapid growth during the COVID-19 pandemic due to unprecedented demand for polymerase chain reaction (PCR) testing. While pandemic-related testing volumes have declined, the installed base of molecular diagnostic instruments has expanded significantly, supporting long-term demand for non-COVID infectious disease testing.

Growth in this market is driven by increasing prevalence of infectious diseases, expansion of syndromic multiplex testing panels, increasing awareness of antimicrobial resistance, and growing demand for rapid diagnostic results that support timely clinical decision-making. Molecular diagnostic technologies are increasingly used in hospital laboratories, reference laboratories, outpatient clinics, and point-of-care settings.

Technology Overview

Molecular diagnostic tests detect pathogen-specific nucleic acid sequences using amplification or sequencing technologies. Polymerase chain reaction (PCR) represents the most widely used molecular diagnostic method due to its high sensitivity, specificity, and adaptability to a wide range of pathogens. Real-time PCR allows quantification of nucleic acids and provides rapid results that can guide treatment decisions.

Isothermal amplification technologies such as loop-mediated isothermal amplification (LAMP) and transcription-mediated amplification (TMA) provide alternatives to PCR that do not require complex thermal cycling equipment. These technologies enable development of portable molecular diagnostic platforms suitable for decentralized testing environments.

Next-generation sequencing (NGS) technologies are increasingly used in infectious disease diagnostics, particularly for pathogen identification, outbreak surveillance, and detection of antimicrobial resistance genes. Sequencing technologies enable unbiased detection of multiple pathogens in complex clinical samples.

Syndromic multiplex panels represent an important segment of the molecular infectious disease diagnostics market. These panels detect multiple pathogens simultaneously from a single sample, enabling comprehensive diagnostic evaluation for conditions such as respiratory infections, gastrointestinal infections, and bloodstream infections.

Advances in sample preparation technologies and automation have improved workflow efficiency and reduced time to result.

Free Customization - Just Ask!.

Key Applications

Molecular diagnostics for infectious diseases are used across a wide range of clinical applications. Respiratory infections represent one of the largest segments, including testing for influenza viruses, respiratory syncytial virus (RSV), SARS-CoV-2, and other respiratory pathogens.

Sexually transmitted infection (STI) testing represents another important application area, including detection of pathogens such as Chlamydia trachomatis, Neisseria gonorrhoeae, and human papillomavirus (HPV).

Hospital-acquired infection testing is used to detect pathogens associated with healthcare-associated infections such as Clostridioides difficile, methicillin-resistant Staphylococcus aureus (MRSA), and vancomycin-resistant Enterococci (VRE).

Gastrointestinal pathogen testing is used to detect organisms associated with diarrhea and foodborne illness.

Bloodstream infection testing supports rapid detection of sepsis-causing pathogens.

Molecular diagnostics are also used in surveillance of emerging infectious diseases and monitoring of antimicrobial resistance patterns.

Market Drivers

Several factors are driving growth in the molecular infectious disease diagnostics market.

Increasing prevalence of infectious diseases continues to create demand for accurate diagnostic testing.

Growth in antimicrobial resistance is increasing need for rapid pathogen identification and resistance detection.

Expansion of syndromic multiplex panels is improving diagnostic efficiency and supporting broader adoption of molecular testing.

Increasing awareness of infection control practices is supporting use of rapid diagnostic tests.

Advances in automation and miniaturization technologies are enabling development of decentralized molecular testing platforms.

Integration of molecular testing into clinical guidelines is supporting adoption in healthcare systems.

Expansion of global travel increases risk of emerging infectious disease transmission, supporting demand for surveillance technologies.

What part of the report do you need?.

Market Segmentation

The molecular infectious disease diagnostics market can be segmented by technology type, disease type, end user, and geographic region.

By technology, PCR represents the dominant segment, followed by isothermal amplification technologies and sequencing-based diagnostics.

By disease type, respiratory infections represent one of the largest segments due to high testing volumes. Other important segments include sexually transmitted infections, gastrointestinal infections, bloodstream infections, and hospital-acquired infections.

End users include hospital laboratories, reference laboratories, public health laboratories, physician offices, and point-of-care settings.

North America represents the largest geographic market due to strong healthcare infrastructure and high adoption of molecular testing technologies. Europe and Asia-Pacific markets are also expanding as healthcare systems invest in improved diagnostic capabilities.

Competitive Landscape

The molecular diagnostics for infectious disease market includes multinational diagnostic companies, specialized molecular diagnostics firms, and emerging biotechnology companies.

Competition is driven by test performance, turnaround time, menu breadth, and cost efficiency.

Instrument placement strategies often involve long-term reagent supply agreements.

Recurring revenue from consumables represents an important component of business models.

Companies are increasingly developing integrated diagnostic platforms combining sample preparation, amplification, detection, and data analysis.

Strategic partnerships between diagnostic companies and public health organizations are common.

Digital connectivity and data management capabilities are becoming important differentiators.

Future Outlook

The molecular infectious disease diagnostics market is expected to continue expanding as healthcare systems emphasize rapid detection of infectious pathogens.

Multiplex testing panels are expected to become more widely used as clinicians seek comprehensive diagnostic information from single tests.

Point-of-care molecular diagnostic platforms are expected to expand access to testing in decentralized settings.

Sequencing technologies may play an increasing role in pathogen identification and antimicrobial resistance detection.

Artificial intelligence tools may improve interpretation of complex molecular diagnostic data.

Overall, molecular diagnostics represent a critical component of modern infectious disease management and public health surveillance. Continued advances in molecular biology technologies, automation, and bioinformatics are expected to support long-term market growth.

The report has hundreds of pages of information including a complete list of Current  United States Medicare Fee Payment Schedules to help sharpen your pricing.    Again, assistance in using the information is normally provided without additional charges.  The report includes detailed breakouts for 15 Countries and 4 Regions.  A detailed breakout for any country in the world is available to purchasers of the report.

 Our research makes you the expert in your organization. Get our research team working for you by ordering all, or a portion, of this comprehensive report.  Your credit card order sends the report to your inbox instantly.  Check all your licensing options but don't worry, your order is available as a credit if you wish to upgrade. We wrote this report and we are ready, by phone or email, to help you use it. As always, assistance, and additional specific data, is provided without additional charges. 

All report data is available in Excel format on request.

SEE the Table of Contents.

GET the Free Sample of this Report.

Many organizations subscribe to some or all of our reports.  You may already have free access to this report. FIND out Here.

ABOUT THE LEAD AUTHOR

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research.  His education includes:

Finance for Senior Executives - Harvard Business School

Market Research  - Burke Institute

M.B.A. (Finance and Policy) - University of British Columbia

B.Sc. (Chemistry) - University of British Columbia

He is an experienced business and clinical professional.  He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping."  He has worked in laboratory testing and management for over 20 years.